inclusion criteria: * patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol * ≥18 years of age * patient is admitted to a hospital (max. 72 hours prior to randomization) due to covid-19 and has a positive sars-cov-2 pcr test * clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the who 10-point clinical progression scale) with covid 19 prior to trial treatment * patient agrees to not participate in another clinical trial from screening until day 56

inclusion criteria: * patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol * ≥18 years of age * patient is admitted to a hospital (max. 72 hours prior to randomization) due to covid-19 and has a positive sars-cov-2 pcr test * clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the who 10-point clinical progression scale) with covid 19 prior to trial treatment * patient agrees to not participate in another clinical trial from screening until day 56

inclusion criteria: patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol ≥18 years of age patient is admitted to a hospital (max. 72 hours prior to randomization) due to covid-19 and has a positive sars-cov-2 pcr test clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the who 10-point clinical progression scale) with covid 19 prior to trial treatment patient agrees to not participate in another clinical trial from screening until day 56

inclusion criteria: patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol ≥18 years of age patient is admitted to a hospital (max. 72 hours prior to randomization) due to covid-19 and has a positive sars-cov-2 pcr test clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the who 10-point clinical progression scale) with covid 19 prior to trial treatment patient agrees to not participate in another clinical trial from screening until day 56